Future Research on and Implementaion of the Bergen 4-Day Treatment - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Future Directions for Research and Implementation of the Bergen 4-Day Treatment for OCD

  • By

  • Eric A. Storch

  • Caitlin M. Pinciotti

  • October 19, 2026

Share

Objective:

The commentary assesses the B4DT trial’s contribution and limitations, patient selection and generalizability, and the treatment’s role and capacity within OCD care.

Approach:
  • Trial: Jelinek et al. randomized 119 adults with OCD to concentrated individual exposure and response prevention (B4DT) or unguided internet-based CBT (iCBT).
  • Commentary: The article discusses the trial’s contribution and limitations, patient selection and generalizability, and B4DT’s place in care and treatment capacity.
Key Findings:
  • B4DT was statistically superior to iCBT, with a large effect size (g = −1.6).
  • At 3 months, response rates were 61.4% with B4DT and 25% with iCBT; remission rates were 42.1% and 13.6%, respectively.
  • B4DT was rated more acceptable than iCBT, and only 3 of 60 participants were lost to 3-month follow-up.
  • Of 253 adults screened, 119 entered the trial; 53 did not meet inclusion criteria and 81 declined, with reasons for refusal unreported.
  • The authors note that the B4DT effects were smaller than those in earlier uncontrolled or waiting-list-controlled studies.
Interpretation:

The trial extends B4DT research by using an active iCBT comparator and an independent research group. The commentary notes that the self-guided ERP condition produced comparatively modest effects and calls for comparisons with an equivalent dose of active ERP delivered over a longer period, as well as studies in naturalistic settings with clinically diverse samples.

Limitations:
  • The self-guided iCBT condition produced comparatively modest effects, and the B4DT effects were smaller than those reported in earlier uncontrolled or waiting-list-controlled studies.
  • Reasons for declining participation were not reported, and the commentary questions how representative the screened and enrolled samples are of the broader OCD population.
  • The B4DT’s role in care and its accessibility at scale remain uncertain. The commentary estimates that the model could treat approximately 45–48 patients per therapist annually.
Conclusion:

The commentary calls for methodologically rigorous comparisons and broad international replication involving patients with differing levels of motivation and engagement.

Sources:

Original Source(s)

Related Content